BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,145 filers reported holding BAXTER INTL INC in Q4 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $176,279 | -22.4% | 5,270 | -0.8% | 0.03% | -27.8% |
| Q1 2024 | $227,127 | +10.6% | 5,314 | +0.0% | 0.04% | 0.0% |
| Q4 2023 | $205,373 | -2.1% | 5,312 | -4.5% | 0.04% | -14.3% |
| Q3 2023 | $209,848 | -18.3% | 5,560 | -1.4% | 0.04% | -22.2% |
| Q2 2023 | $256,947 | +12.4% | 5,640 | +0.0% | 0.05% | +1.9% |
| Q1 2023 | $228,677 | +747.0% | 5,638 | +1640.1% | 0.05% | +307.7% |
| Q4 2019 | $27,000 | – | 324 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
| SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
| Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
| Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
| HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
| Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
| 13D Management LLC | 200,318 | $14,791,000 | 3.77% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
| Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |